LB Pharma needed $350 million to advance a promising schizophrenia candidate at a time when the biotech markets were locked up tight. Fortunately, it wasn’t CEO Heather Turner’s first rodeo.
How LB Rode the Brutal Capital Markets to One of 2025’s Most Successful IPOs